Skip to main content
SpringerLink
Log in

Commentary on Coyle et al., "The assessment of the economic return from controlled clinical trials"

  • Commentary
  • Published:
The European Journal of Health Economics, formerly: HEPAC Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Claxton K, Posnett J (1996) An economic approach to clinical trial design and research priority-setting. Health Economics 5:513–524

  2. Claxton K (1999) The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. Journal of Health Economics 18:341–364

  3. Harper G, Townsend J, Buxton M (1998) The preliminary economic evaluation of health technologies for the prioritization of health technology assessments. A discussion. International Journal of Technology Assesement in Health Care 14:652–662

  4. Felli JC, Hazen GB (1998) Sensitivity analysis and the expected value of perfect information. Medical Decision Making 18:95–109

  5. Fenwick E, Claxton K, Sculpher M, Briggs A (2000) Improving the efficiency and relevance of health technology assessment: The role of iterative decision analytic modelling. Centre for Health Economics discussion paper, University of York

  6. Brennan A, Chilcott J, Kharroubi S, O'Hagan A (2002) A two level Monte Carlo approach to calculating expected value of sample information: how to value a research design. International Health Economics Association conference abstract, San Francisco

  7. Chilcott J, Brennen J, Karnon J, Booth A, Tappenden P. The role of modelling in plamming and prioritising clinical trials. Health Technology Assessment (forthcoming)

  8. Claxton K, Sculpher M, Drummond M (2002) A rational framework for decision making by the National Institute For CIinicaI Excellence (NlCE). Lancet 360:711–715

  9. Claxton K, Neuman PJ, Araki SS, Weinstein M (2001) The value of information: an application to a policy model of Alzheimer's disease. International Journal of Health Technology Assessment 17:38–55

  10. Karnon J (2002) Planning the efficient allocation of research funds: an adapted application of a non-parametric Bayesian value of information analysis. Health Policy 61:329–347

  11. Chilcott J, Holmes MW, Wright JP (2002) Economics of Pulsatile Machine Perfusion for Kidney Preservation before Transplantation and the value of further research. International Health Economics Association conference abstract, San Francisco

  12. Claxton K, Ades T (2002) Efficient research design: an application of value of information analysis to an economic model of zanamivir. International Health Economics Association conference abstract, San Francisco

Download references

Author information

Authors and Affiliations

  1. University of Sheffield, UK

    Jon Karnon, A. Brennan & J. Chilcott

  2. School of Health & Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK

    Jon Karnon

Authors
  1. Jon Karnon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Brennan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Chilcott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jon Karnon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karnon, J., Brennan, A. & Chilcott, J. Commentary on Coyle et al., "The assessment of the economic return from controlled clinical trials". HEPAC 4, 239–240 (2003). https://doi.org/10.1007/s10198-003-0191-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-003-0191-4

Keywords

Search

Navigation